Predictive Biomarkers by Cancer Type

Predictive biomarkers help doctors find out which treatment might be right for you.1 They have been found in many tumor types, including breast, colorectal, lung and prostate cancer.2,3 Here is a list of some of these biomarkers:

Breast
  • ER (estrogen receptor)2,4
  • HER-2/neu2,4
Colorectal
  • EGFR2,4
  • KRAS2,5
  • UGT1A12,5
Gastric Cancer
  • HER-2/neu2
Gastrointestinal Stromal Tumors (GIST)
  • c-KIT2,6
Leukemia/Lymphoma
  • CD20 Antigen2,13
  • CD302,14
  • FIP1L1-PDGFRα2,15
  • PDGFR2,16
  • Philadelphia Chromosome (BCR/ABL)2,7,17
  • PML/RAR α2,8
  • TPMT2,9
  • UGT1A12,10
Lung
  • ALK2,11,12
  • EGFR2,4
  • KRAS2,4
Melanoma
  • BRAF2,12

Print out this Discussion Guide. Use it at your next appointment with your doctor. If you have questions, then talk to your doctor. Ask if there may be a biomarker for your cancer type.

References:
  1. Mishra, A., Verma, M. Cancer Biomarkers: Are We Ready For The Prime Time?” Cancers. 2010: 2: 190-208.
  2. U.S. Food and Drug Administration Website. Table of Pharmacogenomic Biomarkers in Drug Labels. Available at http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm . Accessed November 17, 2011.
  3. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010.
  4. American Cancer Society. Tumor Markers Fact Sheet. Available at http://www.cancer.org/acs/groups/cid/documents/webcontent/003189-pdf.pdf . Accessed March 31, 2011.
  5. Lenz, Heinz-Josef. Established Biomarkers in Colon Cancer. American Society of Clinical Oncology’s 2009 Educational Book. Available at: http://www.asco.org/ASCOv2/Home/Education%20&%20Training/Educational%20Book/PDF%20Files/2009/09EdBk.GI.Colo.04.pdf . Accessed September 15, 2011.
  6. Gonzalez RS, Carlson G, Page AJ, et al. Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome. Am J Clin Pathol. 2011 Jul;136(1):74-80.
  7. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome -positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 110: 2309-2315.
  8. O’Connell P, Madureira P, Berman J, et al. Regulations of S100A10 by the PML/RAR—α oncoprotein. Blood. 2011 117: 4095 4105.
  9. Duffy M, Crown J. A Personalized Approach to Cancer Treatment: How Biomarkers Can Help. Clinical Chemistry 2008: 54:11:1770–1779.
  10. Ribrag V, Koscielny S, Casasnovas O, et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009 113:3307-3313.
  11. Li, Yongjun, et al. Evaluation of EML4-ALK Fusion Proteins in Non–Small Cell Lung Cancer Using Small Molecule Inhibitors. Neoplasia. 2011; 13; 1-11.
  12. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12: 175–80.
  13. Tam C, Otero-Palacios J, Abruzzo LV, et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. British Journal of Haematology, 2008;141, 36–40.
  14. Zhang, M. et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeledanti-CD30 antibody, HeFi-1. PNAS. 2007: 104;20. 8444–8448.
  15. Yamada Y, Sanchez-Aguilera A, Brandt EB, et al. FIP1L1/PDGFR synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. Blood. 2008 112:6. 2500-2507.
  16. Nimer, S. Myelodysplastic syndromes. BLOOD, 2008 _ 111;10. 4841-4851
  17. Boulos C, Mulder HL, Calabrese CR, et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome–positive acute lymphoblastic leukemia. BLOOD. 2011 117: 3585-3595.

Learn about some biomarkers that are being researched for certain kinds of cancers.

Go

Download a Fact Sheet with information on bio-specific medicine and biomarkers.*

Go

* This document is in PDF (portable document format). PDF files require Adobe® Reader®; click here.

The information provided in this site is intended only for residents of the United States.
Copyright © 2011 Pfizer Inc. All rights reserved.

CRI00082